High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice

[1]  R. Auchus,et al.  The role of adrenal derived androgens in castration resistant prostate cancer , 2020, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  P. Troncoso,et al.  Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients. , 2020, European urology oncology.

[3]  Changhong Shi,et al.  Development of patient-derived xenograft models of prostate cancer for maintaining tumor heterogeneity. , 2019, Translational andrology and urology.

[4]  Gang Cai,et al.  PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics , 2019, BMC Cancer.

[5]  Xiaojian Huang,et al.  NOV/CCN3 induces cartilage protection by inhibiting PI3K/AKT/mTOR pathway , 2019, Journal of cellular and molecular medicine.

[6]  H. Beltran,et al.  Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC). , 2019, Journal of Clinical Oncology.

[7]  I. Mills,et al.  The b2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells , 2019 .

[8]  T. Laajala,et al.  Adrenals Contribute to Growth of Castration-Resistant VCaP Prostate Cancer Xenografts. , 2018, The American journal of pathology.

[9]  W. Zwart,et al.  Molecular underpinnings of enzalutamide resistance. , 2018, Endocrine-related cancer.

[10]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[11]  P. Nelson,et al.  Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer , 2018, Clinical Cancer Research.

[12]  D. Feinstein,et al.  CCL2 Induces the Production of β2 Adrenergic Receptors and Modifies Astrocytic Responses to Noradrenaline , 2018, Molecular Neurobiology.

[13]  Evan Bolton,et al.  Database resources of the National Center for Biotechnology Information , 2017, Nucleic Acids Res..

[14]  T. Laajala,et al.  Antiandrogens Reduce Intratumoral Androgen Concentrations and Induce Androgen Receptor Expression in Castration-Resistant Prostate Cancer Xenografts. , 2016, The American journal of pathology.

[15]  D. M. Molina,et al.  Determining direct binders of the Androgen Receptor using a high-throughput Cellular Thermal Shift Assay , 2018, Scientific Reports.

[16]  Y. Tsai,et al.  CCN3 promotes epithelial-mesenchymal transition in prostate cancer via FAK/Akt/HIF-1α-induced twist expression , 2017, Oncotarget.

[17]  Maria K. Jaakkola,et al.  ROTS: An R package for reproducibility-optimized statistical testing , 2017, PLoS Comput. Biol..

[18]  W. Fang,et al.  Hypoxia-induced PLOD2 promotes proliferation, migration and invasion via PI3K/Akt signaling in glioma , 2017, Oncotarget.

[19]  Ximing J. Yang,et al.  Polycomb-Mediated Disruption of an Androgen Receptor Feedback Loop Drives Castration-Resistant Prostate Cancer. , 2017, Cancer research.

[20]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[21]  Henry W. Long,et al.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.

[22]  David S. K. Lu,et al.  Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.

[23]  S. Surapaneni,et al.  Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide. , 2016, Drug metabolism letters.

[24]  Tero Aittokallio,et al.  Optimized design and analysis of preclinical intervention studies in vivo , 2016, Scientific Reports.

[25]  G. Kristiansen,et al.  SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells , 2016, Molecular Cancer Research.

[26]  Song Liu,et al.  Regulators of Androgen Action Resource: a one-stop shop for the comprehensive study of androgen receptor action , 2016, Database J. Biol. Databases Curation.

[27]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[28]  A. Horwich,et al.  Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  T. Ouatas,et al.  Pharmacokinetic Drug Interaction Studies with Enzalutamide , 2015, Clinical Pharmacokinetics.

[30]  M. Nilsson,et al.  Measurement of a Comprehensive Sex Steroid Profile in Rodent Serum by High-Sensitive Gas Chromatography-Tandem Mass Spectrometry. , 2015, Endocrinology.

[31]  A. Bernard,et al.  Impact on abiraterone pharmacokinetics and safety: Open‐label drug–drug interaction studies with ketoconazole and rifampicin , 2015, Clinical pharmacology in drug development.

[32]  P. Troncoso,et al.  Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. , 2015, European urology.

[33]  T. Laajala,et al.  Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model. , 2014, The American journal of pathology.

[34]  S. Balk,et al.  Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis , 2014, Oncogene.

[35]  Zhaohui S. Qin,et al.  Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.

[36]  S. Conzen,et al.  Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer , 2014, Hormones and Cancer.

[37]  T. Kuzel,et al.  CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor , 2014, Oncogene.

[38]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[39]  D. Zheng,et al.  Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade , 2013, Cell.

[40]  Gang Shao,et al.  A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.

[41]  Joshua M. Korn,et al.  An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). , 2013, Cancer discovery.

[42]  Andrew J Armstrong,et al.  Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. , 2013, Endocrine-related cancer.

[43]  T. D. de Reijke,et al.  Prostate cancer: ESMO Consensus Conference Guidelines 2012. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  K. Silverstein,et al.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. , 2013, Cancer research.

[45]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[46]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[47]  Tien-Huang Lin,et al.  CCN3 increases cell motility and ICAM-1 expression in prostate cancer cells. , 2012, Carcinogenesis.

[48]  P. Nelson,et al.  Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. , 2011, Cancer research.

[49]  A. Mizokami,et al.  [Androgen receptor mutation]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[50]  N. Socci,et al.  Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor , 2010, Proceedings of the National Academy of Sciences.

[51]  P. Nelson,et al.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. , 2010, The Journal of clinical investigation.

[52]  A. Balmain,et al.  Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.

[53]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[54]  K. Pienta,et al.  Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. , 2010, Journal of the National Cancer Institute.

[55]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[56]  K. Waltering,et al.  Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. , 2009, Cancer research.

[57]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[58]  B. Perbal.  CCN3: Doctor Jekyll and Mister Hyde , 2008, Journal of Cell Communication and Signaling.

[59]  M. Gleave,et al.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.

[60]  E. Corey,et al.  Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone , 2008, Clinical & Experimental Metastasis.

[61]  E. Antonarakis,et al.  Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  I. Mills,et al.  New androgen receptor genomic targets show an interaction with the ETS1 transcription factor , 2007, EMBO reports.

[63]  Vijayasaradhi Setaluri,et al.  Microtubule-Associated Proteins as Targets in Cancer Chemotherapy , 2007, Clinical Cancer Research.

[64]  D. Tindall,et al.  Molecular regulation of androgen action in prostate cancer , 2006, Journal of cellular biochemistry.

[65]  W. Gerald,et al.  Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. , 2006, Urology.

[66]  S. Srivastava,et al.  Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival , 2006, Oncogene.

[67]  Duane D. Miller,et al.  Structural basis for antagonism and resistance of bicalutamide in prostate cancer , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[68]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[69]  John T. Wei,et al.  The role of prostate specific antigen in screening and management of clinically localized prostate cancer , 2004, International Urology and Nephrology.

[70]  C. Korch,et al.  Molecular characterization of human prostate carcinoma cell lines , 2003, The Prostate.

[71]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[72]  R L Vessella,et al.  Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .

[73]  F. S. French,et al.  Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. , 2001, Cancer research.

[74]  K. Pienta,et al.  VCaP, a cell-based model system of human prostate cancer. , 2001, In vivo.

[75]  I. Melezínek,et al.  The role of prostate specific antigen measurement in the detection and management of prostate cancer. , 2000, Endocrine-related cancer.

[76]  Desok Kim,et al.  Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. , 1998, Cancer research.

[77]  S. Yeh,et al.  D5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells , 1998 .

[78]  J Isola,et al.  Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. , 1997, Cancer research.

[79]  K. Pettersson,et al.  One-step all-in-one dry reagent immunoassays with fluorescent europium chelate label and time-resolved fluorometry. , 1996, Clinical chemistry.

[80]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[81]  P. Riegman,et al.  The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. , 1991, Molecular endocrinology.

[82]  R. Renkawitz,et al.  The glucocorticoid receptor. , 1991, Biochimica et biophysica acta.

[83]  M. Freeman,et al.  Regulation of gene expression in rat prostate by androgen and beta-adrenergic receptor pathways. , 1990, Molecular endocrinology.

[84]  F. Labrie,et al.  Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. , 1989, Journal of steroid biochemistry.

[85]  F. Labrie,et al.  Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. , 1985, Journal of steroid biochemistry.

[86]  R. Horton,et al.  Origin of plasma androstanediol glucuronide in men. , 1984, The Journal of clinical endocrinology and metabolism.

[87]  P. Kelly,et al.  Antifertility effects of LHRH agonists in the male rat and inhibition of testicular steroidogenesis in man. , 1980, International journal of fertility.